id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-N-4462-0003,FDA,FDA-2015-N-4462,Testimony from Daniel Kaczor,Other,Testimony,2016-09-06T04:00:00Z,2016,9,2016-09-06T04:00:00Z,,2016-09-06T14:42:11Z,,0,0,0900006481edf990
FDA-2015-N-4462-0002,FDA,FDA-2015-N-4462,"Point of Care Prothrombin Time/International Normalized Ratio Devices
for Monitoring Warfarin Therapy; Public Workshop; Request for Comments",Notice,Request for Comments,2016-02-17T05:00:00Z,2016,2,2016-02-17T05:00:00Z,2016-04-19T03:59:59Z,2016-09-07T01:00:36Z,2016-03153,0,0,0900006481e71441
FDA-2015-N-4462-0001,FDA,FDA-2015-N-4462,"Point of Care Prothrombin Time/International Normalized Ratio Devices
for Monitoring Warfarin Therapy; Public Workshop; Request for Comments",Notice,Public Meetings,2015-12-15T05:00:00Z,2015,12,2015-12-15T05:00:00Z,2016-02-26T04:59:59Z,2015-12-15T15:12:03Z,2015-31404,0,0,0900006481da6b39